Cargando…

Expression of MAGE-A and NY-ESO-1 cancer/testis antigens in medullary breast cancer: a retrospective immunohistochemical study

AIM: To immunohistochemically evaluate the expression of MAGE-A1, MAGE-A, and NY-ESO-1 cancer/testis (C/T) tumor antigens in medullary breast cancer (MBC) tumor samples and to analyze it in relation to the clinicopathological features. METHODS: This retrospective study included samples from 49 patie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Matković, Božica, Juretić, Antonio, Spagnoli, Giulio C, Šeparović, Viktor, Gamulin, Marija, Šeparović, Robert, Šarić, Nera, Bašić-Koretić, Martina, Novosel, Irena, Krušlin, Božo
Formato:	Texto
Lenguaje:	English
Publicado:	Croatian Medical Schools 2011
Materias:	Clinical Science
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3081216/ https://www.ncbi.nlm.nih.gov/pubmed/21495200 http://dx.doi.org/10.3325/cmj.2011.52.171

Ejemplares similares

Immunohistochemical analysis of the expression of MAGE-A and NY-ESO-1 cancer/testis antigens in diffuse large B-cell testicular lymphoma
por: Hudolin, Tvrtko, et al.
Publicado: (2013)

Clinicopathological assessment of cancer/testis antigens NY-ESO-1 and MAGE-A4 in osteosarcoma
por: Hashimoto, Kazuhiko, et al.
Publicado: (2022)

MAGE-A3/4 and NY-ESO-1 antigens expression in metastatic esophageal squamous cell carcinoma
por: Bujas, T., et al.
Publicado: (2011)

Expression of MAGE‐A and NY‐ESO‐1 cancer/testis antigens is enriched in triple‐negative invasive breast cancers
por: Raghavendra, Ashwini, et al.
Publicado: (2018)

Combinational expression of tumor testis antigens NY-ESO-1, MAGE-A3, and MAGE-A4 predicts response to immunotherapy in mucosal melanoma patients
por: Freiberger, Sandra N., et al.
Publicado: (2022)

Involvement of NY-ESO-1 and MAGE-A4 in the pathogenesis of desmoid tumors
por: Hashimoto, Kazuhiko, et al.
Publicado: (2023)

Clinicopathological Assessment of Cancer/Testis Antigens NY-ESO-1 and MAGE-A4 in Highly Aggressive Soft Tissue Sarcomas
por: Hashimoto, Kazuhiko, et al.
Publicado: (2022)

Centrosomal Localisation of the Cancer/Testis (CT) Antigens NY-ESO-1 and MAGE-C1 Is Regulated by Proteasome Activity in Tumour Cells
por: Pagotto, Anna, et al.
Publicado: (2013)

Expression of MAGE-A3, NY-ESO-1, LAGE-1 and PRAME in urothelial carcinoma
por: Dyrskjøt, L, et al.
Publicado: (2012)

Immunohistochemical expression and clinicopathological assessment of PD-1, PD-L1, NY-ESO-1, and MAGE-A4 expression in highly aggressive soft tissue sarcomas
por: Hashimoto, Kazuhiko, et al.
Publicado: (2022)

MAGE-A4, NY-ESO-1 and SAGE mRNA expression rates and co-expression relationships in solid tumours
por: Ishihara, Mikiya, et al.
Publicado: (2020)

NY-ESO-1 Cancer Testis Antigen Demonstrates High Immunogenicity in Triple Negative Breast Cancer
por: Ademuyiwa, Foluso O., et al.
Publicado: (2012)

Myeloid-derived suppressor cells infiltration in non-small-cell lung cancer tumor and MAGE-A4 and NY-ESO-1 expression
por: Hou, Zhenbo, et al.
Publicado: (2020)

Correction: NY-ESO-1 Cancer Testis Antigen Demonstrates High Immunogenicity in Triple Negative Breast Cancer
por: Ademuyiwa, Foluso O., et al.
Publicado: (2012)

Cancer‐testis antigens PRAME and NY‐ESO‐1 correlate with tumour grade and poor prognosis in myxoid liposarcoma
por: Iura, Kunio, et al.
Publicado: (2015)

Unleashing the immune response to NY-ESO-1 cancer testis antigen as a potential target for cancer immunotherapy
por: Raza, Afsheen, et al.
Publicado: (2020)

NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives
por: Thomas, Remy, et al.
Publicado: (2018)

NY-ESO-1 antigen expression and immune response are associated with poor prognosis in MAGE-A4-vaccinated patients with esophageal or head/neck squamous cell carcinoma
por: Ueda, Shugo, et al.
Publicado: (2018)

Ureteral metastasis as the first and sole manifestation of gastric cancer dissemination
por: Bisof, Vesna, et al.
Publicado: (2010)

Transient expression of the cancer/testis cancer antigen NY-ESO-1 in Nicotiana benthamiana using a PVX-based viral vector
por: Lacorte, Cristiano, et al.
Publicado: (2014)

Prevalence of plasma autoantibody against cancer testis antigen NY-ESO-1 in HTLV-1 infected individuals with different clinical status
por: Shiohama, Yasuo, et al.
Publicado: (2017)

Evaluation of Production Protocols for the Generation of NY-ESO-1-Specific T Cells
por: Gong, Wenjie, et al.
Publicado: (2021)

Dose-dependent effects of NY-ESO-1 protein vaccine complexed with cholesteryl pullulan (CHP-NY-ESO-1) on immune responses and survival benefits of esophageal cancer patients
por: Kageyama, Shinichi, et al.
Publicado: (2013)

Primary undifferentiated carcinoma of rete testis with extensive peritoneal carcinomatosis and fatal outcome: Case report
por: Petrović, Andreja, et al.
Publicado: (2023)

Analysis of GAGE, NY-ESO-1 and SP17 cancer/testis antigen expression in early stage non-small cell lung carcinoma
por: Gjerstorff, Morten F, et al.
Publicado: (2013)

NY-ESO-1 tumour associated antigen is a cytoplasmic protein detectable by specific monoclonal antibodies in cell lines and clinical specimens
por: Schultz-Thater, E, et al.
Publicado: (2000)

Extramammary Paget disease shows differential expression of B7 family members B7-H3, B7-H4, PD-L1, PD-L2 and cancer/testis antigens NY-ESO-1 and MAGE-A
por: Pourmaleki, Maryam, et al.
Publicado: (2019)

NY-ESO-1 antibody as a novel tumour marker of gastric cancer
por: Fujiwara, S, et al.
Publicado: (2013)

NY-ESO-1 as a potential immunotherapeutic target in renal cell carcinoma
por: Giesen, Eva, et al.
Publicado: (2014)

NY-ESO-1 expression in sarcomas: A diagnostic marker and immunotherapy target
por: Lai, Jin-Ping, et al.
Publicado: (2012)

NY-ESO-1 expression in DCIS: A new predictor of good prognosis
por: Coombes, R. Charles, et al.
Publicado: (2017)

Pushing forward in sarcoma with a new TCR targeting NY-ESO-1
por: Al-Marayaty, Rusul, et al.
Publicado: (2023)

Identification of Ny-Eso-1 Epitopes Presented by Human Histocompatibility Antigen (Hla)-Drb4*0101–0103 and Recognized by Cd4(+)T Lymphocytes of Patients with Ny-Eso-1–Expressing Melanoma
por: Jäger, Elke, et al.
Publicado: (2000)

Human CLEC9A antibodies deliver NY-ESO-1 antigen to CD141(+) dendritic cells to activate naïve and memory NY-ESO-1-specific CD8(+) T cells
por: Masterman, Kelly-Anne, et al.
Publicado: (2020)

First-in-human phase I clinical trial of the NY-ESO-1 protein cancer vaccine with NOD2 and TLR9 stimulants in patients with NY-ESO-1-expressing refractory solid tumors
por: Ishihara, Mikiya, et al.
Publicado: (2020)

Tumor-Infiltrating T Cells Correlate with NY-ESO-1-Specific Autoantibodies in Ovarian Cancer
por: Milne, Katy, et al.
Publicado: (2008)

NY-ESO-1 antigen-reactive T cell receptors exhibit diverse therapeutic capability
por: Sommermeyer, Daniel, et al.
Publicado: (2013)

Anti-NY-ESO-1 autoantibody may be a tumor marker for intrahepatic cholangiocarcinoma
por: Zhang, Zhen, et al.
Publicado: (2017)

Biomarker correlates with response to NY-ESO-1 TCR T cells in patients with synovial sarcoma
por: Gyurdieva, Alexandra, et al.
Publicado: (2022)

Current advances in cancer vaccines targeting NY-ESO-1 for solid cancer treatment
por: Zhou, Hong, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_guiu86tgssbdgb3l0tb298almp